Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost‐effectiveness analysis-Reference-Cited by-同舟云学术

Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost‐effectiveness analysis

Published:2024-08-19 Issue: Volume: Page:
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Horton William B.¹^ORCID,Dart Marina E.¹,Kavuru Varun S.²,Girton Mark R.³,Jin Ruyun⁴

Affiliation:

1. Division of Endocrinology and Metabolism University of Virginia School of Medicine Charlottesville Virginia USA

2. Department of Internal Medicine University of Virginia School of Medicine Charlottesville Virginia USA

3. Department of Pathology University of Michigan School of Medicine Ann Arbor Michigan USA

4. Department of Public Health Sciences University of Virginia School of Medicine Charlottesville Virginia USA

Funder

American Heart Association

Publisher

Wiley

Reference24 articles.

1. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association;Pop‐Busui R;Diabetes Care,2022

2. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from diabetes technology society;Yeung AM;Prog Cardiovasc Dis,2023

3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials;Zelniker TA;Lancet,2019

5. Centers for Disease Control and Prevention.National Diabetes Statistics Report website. Accessed 26 January 2023.https://www.cdc.gov/diabetes/data/statistics-report/index.html